1 unknown. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
Follow Leukemia Lymphocytic Acute (ALL) in Relapse: new trials by email Literature Review of Leukemia Lymphocytic Acute (ALL) in Relapse trials Research Report on Leukemia Lymphocytic Acute (ALL) in Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma. XYF19 CAR-T cell, Cyclophosphamide, Fludarabine - Leukemia Lymphocytic Acute (ALL) in Relapse, Leukemia Lymphocytic Acute (All) Refractory | Phase 1 | Unknown | Xijing Hospital | 40 | 2019-08-01 | 2019-07-30 |
Lymphoma, B-Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Cyclophosphamide (1) · fludarabine (1)
Xijing Hospital (1)
China (1)